Polycystic ovary syndrome — compounds assessed
The 2 compounds the Institute assesses in polycystic ovary syndrome.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Pulsatile administration by pump induces ovulation in hypothalamic amenorrhoea with reported ovulation rates above 80 % per cycle in selected patients — This application requires a pump delivering pulses every 60 to 90 minutes. It cannot be reproduced by…
Moderate -
Kisspeptin-54 has been used as an oocyte-maturation trigger in assisted reproduction with reported reduction in ovarian hyperstimulation risk compared with human chorionic gonadotropin — The assisted-reproduction work used kisspeptin-54, not the decapeptide…
Low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.